Targeting specific signaling pathways in a type of leukemia
Official title: Targeting Kinase Inhibitor Induced Signaling Plasticity in Patients with Ph-Like ALL
Funded at Loma Linda University · NIH-11030456 · Data updated 2026-11-12
This study is looking for better ways to treat people with a tough type of leukemia called Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) by testing new treatments that target specific proteins involved in the cancer's growth, hoping to help patients feel better with fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loma Linda University NIH-funded |
| Lab location | 1 site (Loma Linda, UNITED STATES) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $193,104 |
| NIH project number | 7K22CA251649-03 |
| Project ID | NIH-11030456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Philadelphia chromosome-like acute lymphoblastic leukemia, particularly those who have not responded well to standard treatments.
✕Less likely to help
Patients with other types of leukemia or those who do not have Philadelphia chromosome-like ALL may not benefit from this research.
What this research studies
This research investigates how to improve treatment for patients with Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), a high-risk subtype of leukemia. The study focuses on the effects of inhibiting certain kinases that are involved in the cancer's growth and survival. By using a combination of targeted therapies, the researchers aim to identify effective treatment strategies that minimize toxicity while maximizing cancer cell death. Patients may be involved in trials that test these new treatment approaches to see if they can improve outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Ph-like ALL.
How similar studies have gone: Previous research has shown promise in targeting similar signaling pathways in other types of leukemia, suggesting that this approach may be effective.
Where this research is happening
-
Loma Linda University
Loma Linda, United States Active
Researchers
- Principal investigator: Hurtz, Christian — Loma Linda University
- Study coordinator: Hurtz, Christian
Related research
Other NIH-funded projects on the same topics.
-
LLU's shared-use facility to advance cellular therapy and regenerative medicine
A new shared laboratory facility at Loma Linda University will enable cell therapy and regenerative medicine work that could help people with cancer, blood disorders, and immune-related conditions.
-
Brain support cells in newborn brain injury after birth asphyxia
This grant studies how brain-supporting cells called pericytes affect brain damage after a newborn experiences a lack of oxygen at birth, with potential to guide new treatments.
-
Digitally supported community workers helping HPB cancer patients receive early palliative care
A pilot program uses digital tools and community health workers to bring early palliative care and support to people with HPB cancers and their caregivers.
-
REASON Score: an epigenetic and clinicopathologic approach to predict survival risk in early oral cancer
A new biomarker-based score using DNA methylation and clinicopathology to predict survival risk for people with early-stage oral squamous cell carcinoma.
-
Effects of chronic low oxygen on brain blood flow control in newborns
A study in newborns and animal models will explore how chronic low oxygen affects the brain’s ability to keep blood flow steady, which is crucial for preventing brain injuries.
-
Endothelial potassium channels and brain aging
A study in mice and aging adults to understand how tiny blood vessels in the brain fail and contribute to dementia, with the goal of identifying targets to protect brain blood flow in people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.